Startup targets $250m concussion market with AI diagnostics

This article is a part of Startup Spotlight, a series that features young, up-and-coming startups.

Image credit: Timmy Loen

Michel Birnbaum witnessed a tragic pattern repeat across US and European hospitals for years. Families waited weeks for neurology consultations while clinicians made critical decisions without objective data. He co‑founded Mindsigns Health to assist clinicians with automated, clinical‑grade precision.

😟 Problem

Mental and neurological disorders affect one in five people globally. Diagnostics remain dangerously inefficient. Standard EEG tests require manual interpretation that consumes hours of specialist time.

Psychiatric care depends on episodic patient reporting rather than continuous data. This inefficiency causes diagnostic bottlenecks and limits clinical capacity.

💡 Solution

The company offers a unified AI platform with two core components:

• NeuroBrowser automates EEG signal analysis to cut interpretation time from hours to minutes.
• GenMind provides mobile remote monitoring using speech and behavioral patterns to track cognitive impairment.
• The system holds ISO certification for medical device software.

Image credit: Timmy Loen

📊 Market size

The entry point is the US$250 million US concussion care sector. This niche benefits from existing reimbursement codes and underserved patient needs. The broader neuro-diagnostics and cognitive-monitoring market exceeds US$25 billion.

Bottom-up projections suggest a near-term annual recurring revenue potential between US$35 million and US$80 million.

🤝 Team

• Michel Birnbaum (CEO) scaled multiple healthcare ventures through IPOs and brings deep regulatory strategy expertise.
• Thibaud Lefevre (CTO) leads engineering and specializes in building regulated, cloud-based health-tech platforms.
• Prof Justin Dauwels (CSO) serves as an expert in neural signal processing with over 300 peer-reviewed publications.
• Benoit Delacrose (CISO) architected the compliance framework that secured ISO 13485 certification.
• Dr Manu Sidhu (CMO) applies NHS clinical experience to ensure product workflows match frontline medical needs.

🚀 Traction

• 10 Tier-1 clinical and research institutions support the platform across the US and Asia.
• Ongoing validation includes three active clinical trials.
• The company secured US$2 million in grants and paid pilots involving data from 1,000 patients.

🏆 Competition

Legacy vendors like Persyst dominate hospital settings but lack mobile capabilities. Digital apps like Kintsugi track symptoms without validated clinical‑grade behavioral data.

💰 Financials